Breaking News, Collaborations & Alliances

ABL and Odimma Therapeutics Enter Development Agreement

Join forces in personalized cancer immunotherapy.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ABL Europe (ABL), a pure play contract development and manufacturing organization (CDMO) specialized in development and manufacturing of virus for vaccine candidates, gene and cancer therapies, and Odimma Therapeutics, a biotech focusing on personalized cancer immunotherapy, have signed a development agreement. ABL will manufacture the viral component of Odimma’s proprietary immunization platform ODI-2001. The viral component present in ODI-2001 plays the role of both a strong immune ad...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters